EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma

Yufei Lan, Xiaodie Li, Boyang Liu, Jiankun Lu, Boming Zuo, Yue Wang, Shuting Cao, Xin Fu, Qu Yue, Xin Luo, Xiangyang Zhong, Yaoyuan Dong und 11 weitere

Drug Resistance Updates · 2024-09 · 76 · 101122

DOI: 10.1016/j.drup.2024.101122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-09. Verfasst von Yufei Lan und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnos…. Hauptthemen laut MEDLINE: Glioblastoma, Temozolomide, Brain Neoplasms, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

O6-methylguanine DNA methyltransferase (MGMT) is a crucial determinant of temozolomide (TMZ) sensitivity in patients with glioblastoma (GBM). The therapeutic potential of small interfering RNA (siRNA) targeting MGMT to enhance TMZ sensitivity has been hampered by serum nuclease degradation, off-target effects, poor accumulation at tumor sites, and low circulation in blood stream. In this study, we developed a framework nucleic acid-based nanoparticles (FNN), which is constructed from a six-helix DNA bundle, to encapsulate and protect siMGMT for improving TMZ sensitivity in GBM treatment. For better blood-brain barrier (BBB) penetration and GBM targeting, we conjugated Angiopep-2 (ANG) targeting modules to each end of the FNN. Nucleolin (NCL)-responsive locks were engineered along the sides of the six-helix DNA bundle, which safeguard siMGMT before tumor entry. Upon interaction with tumor-overexpressed NCL, these locks unlock, exposing siMGMT, this allows for effective suppression of MGMT, resulting in a significant improvement of TMZ therapeutic efficacy in GBM. This innovative strategy has the potential to transform the current treatment landscape for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTemozolomideBrain NeoplasmsAntineoplastic Agents, AlkylatingNanoparticlesBlood-Brain BarrierHumansAnimalsDrug Resistance, NeoplasmCell Line, TumorRNA-Binding ProteinsDNA Repair EnzymesDNA Modification MethylasesNucleolinPhosphoproteinsTumor Suppressor ProteinsRNA, Small InterferingNucleic AcidsPeptides

Stichwörter der Autor:innen

DNA frameworkDNA nanotechnologyGlioblastomaSiRNATemozolomide sensitivity

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingAngiopep-2RNA-Binding ProteinsDNA Repair EnzymesDNA Modification MethylasesNucleolinPhosphoproteinsTumor Suppressor ProteinsRNA, Small Interfering

Autor:innen und Institutionen

  • Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key…
  • Department of Neurosurgery, Department of Neuro-oncological Surgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrova…
  • Division of Physical Biology, CAS Key Laboratory of Interfacial Physics and Technology, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 201800, Chi…
  • Xiangfu Laboratory, Jiashan 314102, China.
  • Department of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu 225001, China. Electronic address: sybilzuo@163.com.
  • Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China. Electronic address: zhaoyan@szbl.ac.cn.

Zitieren

APA

Lan, Y., Li, X., Liu, B., Lu, J., Zuo, B., Wang, Y., Cao, S., Fu, X., Yue, Q., Luo, X., Zhong, X., Dong, Y., Wang, Z., Yang, T., Xie, X., Zeng, T., Zhang, M., Wang, Y., Shen, Y., …, & Guo, H. (2024). Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma. Drug Resistance Updates, 76, 101122. https://doi.org/10.1016/j.drup.2024.101122

Vancouver

Lan Y, Li X, Liu B, Lu J, Zuo B, Wang Y, et al. Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma. Drug Resistance Updates. 2024;76:101122. doi:10.1016/j.drup.2024.101122

BibTeX
@article{Lan2024,
  author = {Lan, Yufei and Li, Xiaodie and Liu, Boyang and Lu, Jiankun and Zuo, Boming and Wang, Yue and Cao, Shuting and Fu, Xin and Yue, Qu and Luo, Xin and Zhong, Xiangyang and Dong, Yaoyuan and Wang, Zhao and Yang, Tao and Xie, Xinyun and Zeng, Tianci and Zhang, Manqing and Wang, Yuankai and Shen, Yixiong and Zuo, Huaqin and Zhao, Yan and Zhang, Chao and Guo, Hongbo},
  title = {Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma},
  journal = {Drug Resistance Updates},
  year = {2024},
  volume = {76},
  pages = {101122},
  doi = {10.1016/j.drup.2024.101122}
}
Kostenlos starten →